FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385597054> ?p ?o ?g. }

• W4385597054 abstract "Abstract Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study aimed to examine anlotinib plus icotinib as a first-line treatment option for advanced NSCLC carrying EGFR mutation with or without concurrent mutations. Methods This phase 2, single-arm, multicenter trial (ClinicalTrials.gov NCT03736837) was performed at five hospitals in China from December 2018 to November 2020. Non-squamous NSCLC cases with EGFR-sensitizing mutations were treated with anlotinib and icotinib. The primary endpoint was progression-free survival (PFS). Secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and toxicity. Results Sixty participants were enrolled, including 31 (52%) and 29 (48%) with concurrent mutations and pathogenic concurrent mutations, respectively. The median follow-up was 26.9 (range, 15.0-38.9) months. ORR and DCR were 68.5% and 98.2%, respectively. Median PFS was 15.1 (95%CI: 12.6–17.6) months which met the primary endpoint, median DoR was 13.5 (95%CI: 10.0-17.1) months, and median OS was 30.0 (95%CI: 25.5–34.5) months. Median PFS and OS in patients with pathogenic concurrent mutations were 15.6 (95%CI: 12.5–18.7) months and not reached (95%CI: 17.46 months to not reached), respectively. All patients experienced TRAEs, including 26 (43%) and 1 (1.7%) who had grade ≥ 3 and serious treatment-related adverse events (TRAEs). Conclusions Anlotinib combined with icotinib was effective and well-tolerated as a first-line treatment option for EGFR mutation-positive advanced NSCLC with or without concurrent mutations. Trial registration ClinicalTrials.gov identifier: NCT03736837." @default.
• W4385597054 created "2023-08-05" @default.
• W4385597054 creator A5006688367 @default.
• W4385597054 creator A5019704254 @default.
• W4385597054 creator A5019840134 @default.
• W4385597054 creator A5022356244 @default.
• W4385597054 creator A5033429089 @default.
• W4385597054 creator A5036390761 @default.
• W4385597054 creator A5036950610 @default.
• W4385597054 creator A5050827327 @default.
• W4385597054 creator A5051025874 @default.
• W4385597054 creator A5056496295 @default.
• W4385597054 creator A5065440466 @default.
• W4385597054 creator A5071612416 @default.
• W4385597054 creator A5072319168 @default.
• W4385597054 creator A5073746039 @default.
• W4385597054 creator A5077990905 @default.
• W4385597054 creator A5081970028 @default.
• W4385597054 creator A5083520305 @default.
• W4385597054 creator A5086664284 @default.
• W4385597054 date "2023-08-05" @default.
• W4385597054 modified "2023-10-13" @default.
• W4385597054 title "Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study" @default.
• W4385597054 cites W1905131997 @default.
• W4385597054 cites W1970413157 @default.
• W4385597054 cites W2059145105 @default.
• W4385597054 cites W2076357933 @default.
• W4385597054 cites W2089335658 @default.
• W4385597054 cites W2099742478 @default.
• W4385597054 cites W2154803909 @default.
• W4385597054 cites W2163186602 @default.
• W4385597054 cites W2163351155 @default.
• W4385597054 cites W2170049625 @default.
• W4385597054 cites W2185391357 @default.
• W4385597054 cites W2519152232 @default.
• W4385597054 cites W2521967673 @default.
• W4385597054 cites W2534288116 @default.
• W4385597054 cites W2535426958 @default.
• W4385597054 cites W2723308302 @default.
• W4385597054 cites W2747505649 @default.
• W4385597054 cites W2770828094 @default.
• W4385597054 cites W2794883050 @default.
• W4385597054 cites W2883896246 @default.
• W4385597054 cites W2885503610 @default.
• W4385597054 cites W2888363175 @default.
• W4385597054 cites W2889366471 @default.
• W4385597054 cites W2890155867 @default.
• W4385597054 cites W2902112970 @default.
• W4385597054 cites W2904414029 @default.
• W4385597054 cites W2921428217 @default.
• W4385597054 cites W2924358800 @default.
• W4385597054 cites W2937223370 @default.
• W4385597054 cites W2962129043 @default.
• W4385597054 cites W2967108178 @default.
• W4385597054 cites W2967210753 @default.
• W4385597054 cites W2978677918 @default.
• W4385597054 cites W3014961679 @default.
• W4385597054 cites W3025992067 @default.
• W4385597054 cites W3128870202 @default.
• W4385597054 cites W3156170207 @default.
• W4385597054 cites W3165543715 @default.
• W4385597054 cites W3173300716 @default.
• W4385597054 cites W3176250615 @default.
• W4385597054 cites W3201632112 @default.
• W4385597054 cites W3212489250 @default.
• W4385597054 cites W4200561103 @default.
• W4385597054 cites W4207054516 @default.
• W4385597054 cites W4280533169 @default.
• W4385597054 doi "https://doi.org/10.1186/s12943-023-01823-w" @default.
• W4385597054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37543587" @default.
• W4385597054 hasPublicationYear "2023" @default.
• W4385597054 type Work @default.
• W4385597054 citedByCount "1" @default.
• W4385597054 crossrefType "journal-article" @default.
• W4385597054 hasAuthorship W4385597054A5006688367 @default.
• W4385597054 hasAuthorship W4385597054A5019704254 @default.
• W4385597054 hasAuthorship W4385597054A5019840134 @default.
• W4385597054 hasAuthorship W4385597054A5022356244 @default.
• W4385597054 hasAuthorship W4385597054A5033429089 @default.
• W4385597054 hasAuthorship W4385597054A5036390761 @default.
• W4385597054 hasAuthorship W4385597054A5036950610 @default.
• W4385597054 hasAuthorship W4385597054A5050827327 @default.
• W4385597054 hasAuthorship W4385597054A5051025874 @default.
• W4385597054 hasAuthorship W4385597054A5056496295 @default.
• W4385597054 hasAuthorship W4385597054A5065440466 @default.
• W4385597054 hasAuthorship W4385597054A5071612416 @default.
• W4385597054 hasAuthorship W4385597054A5072319168 @default.
• W4385597054 hasAuthorship W4385597054A5073746039 @default.
• W4385597054 hasAuthorship W4385597054A5077990905 @default.
• W4385597054 hasAuthorship W4385597054A5081970028 @default.
• W4385597054 hasAuthorship W4385597054A5083520305 @default.
• W4385597054 hasAuthorship W4385597054A5086664284 @default.
• W4385597054 hasBestOaLocation W43855970541 @default.
• W4385597054 hasConcept C121608353 @default.
• W4385597054 hasConcept C126322002 @default.
• W4385597054 hasConcept C143998085 @default.
• W4385597054 hasConcept C197934379 @default.
• W4385597054 hasConcept C203092338 @default.
• W4385597054 hasConcept C2776256026 @default.
• W4385597054 hasConcept C2779438470 @default.

• next